If they are not improving, or they are getting worse, that is worth raising with your prescriber or pharmacist (see when to check with a clinician, above)
Signs and symptoms may include: nausea, diarrhea, vomiting, and constipation
For obesity management, NICE has issued relevant guidance and technology appraisals that define NHS eligibility criteria which are distinct from marketing authorisation alone: NICE TA875 covers semaglutide (Wegovy) for managing overweight and obesity, with specific BMI and comorbidity eligibility criteria and requirements for specialist service involvement
Muni Swamy G, Ramesh G, Devi Prasad R, Meriga B (2022) Astragalin, (3-O-glucoside of kaempferol), isolated from Moringa oleifera leaves modulates leptin, adiponectin secretion and inhibits adipogenesis in 3T3-L1 adipocytes
That would ideally be in addition to once again offering GLP-1 medications